Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Croatia | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Norway | Peru | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United States | Uruguay
Approved Indications: Injuries/wounds Unspecified
Known Adverse Events: None
Company: Fundación para la Investigación Biomédica Hospital Gregorio Marañón
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: Czech Republic, Germany, Italy, Spain, Sweden
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Injuries/wounds Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
FGTW2101 | P3 |
Recruiting |
Injuries/wounds Unspecified |
2026-04-30 |